Our latest CPIA report features analysis on the Biotechnology sector. Clinical Professionals Group CEO, Yvette Cleland comments: “The UK biotech businesses focused within research and experimental development have risen by 65% since 2016 and the Golden Triangle of London/Oxford and Cambridge accounts for 35% of this concentration of companies. Annual investment reached 2.2 billion in
The UK biotech Bicycle Therapeutics announced a new partnership with the Dementia Discovery Fund (DDF) to use its novel platform to create new therapies for neurodegenerative diseases, that include dementia. The last decade has seen a run of late-stage drug failures in Alzheimer’s disease, and 2019 alone has seen two major programmes crash in the phase 3
An alliance of pharmaceutical and biotechnology industry associations, researchers and patient groups have asserted that the Council of the European Union needs to maintain the competitive timelines for assessment set out in the European Commission’s proposed regulation on clinical trials if they want to keep Europe at the front end of biopharmaceutical innovation. The alliance
Fresh from linking up with Cambridge University to find therapies for Alzheimer’s and Parkinson’s disease, Elan Corporation announced today that they have signed another academic pact, this time with Ireland’s University College Dublin. An initiative has been announced which is designed to create “a leadership position in the global biotechnology industry”, says Elan, adding that
